AIMS: Herpes virus entry mediator (HVEM) is considered to be a molecular 'switch' for immune responses, and a role in immune modification has been reported. The aim of this study was to assess whether HVEM-mediated immune suppression could protect against experimental autoimmune myocarditis (EAM) induced by myosin. METHODS AND RESULTS: We constructed HVEM-expressing adenovirus (AdHVEM) and fusion protein HVEM-Ig and evaluated their roles in immunoregulation in vitro and in vivo. Immunoregulation of dendritic cells (DCs) infected with recombinant virus or treated with HVEM-Ig was then studied. DCs transfected with AdHVEM (DC-AdHVEM) were protected against EAM, whereas HVEM-Ig had no protective effect. Further study showed that DC-AdHVEMs produced a regulatory cytokine, IL-10, which had further effects on induction of IL-10 producing CD4(+) T cells. This subset of T cells was then responsible for the protection against EAM. CONCLUSION: Myosin-DC-AdHVEM cell gene therapy appears to be a safe and effective way of inhibiting the development of EAM. The signal induced by HVEM seems to play different roles in different cells.
AIMS: Herpes virus entry mediator (HVEM) is considered to be a molecular 'switch' for immune responses, and a role in immune modification has been reported. The aim of this study was to assess whether HVEM-mediated immune suppression could protect against experimental autoimmune myocarditis (EAM) induced by myosin. METHODS AND RESULTS: We constructed HVEM-expressing adenovirus (AdHVEM) and fusion protein HVEM-Ig and evaluated their roles in immunoregulation in vitro and in vivo. Immunoregulation of dendritic cells (DCs) infected with recombinant virus or treated with HVEM-Ig was then studied. DCs transfected with AdHVEM (DC-AdHVEM) were protected against EAM, whereas HVEM-Ig had no protective effect. Further study showed that DC-AdHVEMs produced a regulatory cytokine, IL-10, which had further effects on induction of IL-10 producing CD4(+) T cells. This subset of T cells was then responsible for the protection against EAM. CONCLUSION:Myosin-DC-AdHVEM cell gene therapy appears to be a safe and effective way of inhibiting the development of EAM. The signal induced by HVEM seems to play different roles in different cells.
Authors: Vicky W W Tsai; Mohammad G Mohammad; Ornella Tolhurst; Samuel N Breit; Paul E Sawchenko; David A Brown Journal: J Neurosci Date: 2011-11-30 Impact factor: 6.167
Authors: H Kotani; K Masuda; R Tamagawa-Mineoka; T Nomiyama; F Soga; M Nin; J Asai; S Kishimoto; N Katoh Journal: Clin Exp Immunol Date: 2012-06 Impact factor: 4.330
Authors: Ping Chen; William Tucker; Susan Hannes; Baoying Liu; Han Si; Ankur Gupta; Richard W J Lee; H Nida Sen; Robert B Nussenblatt Journal: Invest Ophthalmol Vis Sci Date: 2014-12-16 Impact factor: 4.799